NCT03333356 - Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Patients With High-risk MIBC

Interventions

RADIATION

pelvic radiotherapy

adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).

Trial Locations (17)

13385

CHU La Timone, Marseille

14000

Centre Francois Baclesse, Caen

21079

Centre Georges-Francois Leclerc, Dijon

31059

Institut Claudius Regaud, Toulouse

31076

Clinique Pasteur, Toulouse

33076

Institut Bergonie, Bordeaux

35760

Chp Saint-Gregoire, Saint-Grégoire

38043

Chu Grenoble, Grenoble

42270

Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez

44805

ICO - site René Gauducheau, Saint-Herblain

49055

ICO Paul Papin, Angers

56100

Groupe Hospitalier Bretagne Sud, Lorient

59000

Centre Oscar Lambret, Lille

69008

Centre Léon Bérard, Lyon

75010

Saint Louis, Paris

75015

Hopital Europeen Georges Pompidou, Paris

87042

Hôpital Universitaire Dupuytren, Limoges

All Listed Sponsors

lead

UNICANCER

OTHER